UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ponatinib: A Review of Efficacy and Safety

Current cancer drug targets, 2018-01, Vol.18 (9), p.847-856

2018

Volltextzugriff (PDF)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Frontiers in oncology, 2021-02, Vol.10, p.610820-610820

2021

Volltextzugriff (PDF)

Maintenance therapy in AML: The past, the present and the future

American journal of hematology, 2019-11, Vol.94 (11), p.1254-1265

2019

Volltextzugriff (PDF)

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Cancers, 2023-10, Vol.15 (20), p.5060

2023

Volltextzugriff (PDF)

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 -Mutated AML Patients

Journal of clinical medicine, 2023-05, Vol.12 (11), p.3647

2023

Volltextzugriff (PDF)

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?

Cancers, 2023-12, Vol.16 (1), p.73

2023

Volltextzugriff (PDF)

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

Annals of hematology, 2015-03, Vol.94 (3), p.393-397

2015

Volltextzugriff (PDF)

How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review

Leukemia research, 2014-12, Vol.38 (12), p.1392-1398

2014

Volltextzugriff (PDF)

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

Cancers, 2023-12, Vol.16 (1), p.42

2023

Volltextzugriff (PDF)

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia

Mediterranean journal of hematology and infectious diseases, 2020-09, Vol.12 (1), p.e2020062-e2020062

2020

Volltextzugriff (PDF)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

Cancers, 2021-06, Vol.13 (13), p.3214

2021

Volltextzugriff (PDF)

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Cancers, 2022-06, Vol.14 (12), p.2843

2022

Volltextzugriff (PDF)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

Therapeutic Advances in Hematology, 2019, Vol.10, p.2040620719826444-2040620719826444

2019

Volltextzugriff (PDF)

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option

Clinical drug investigation, 2018-05, Vol.38 (5), p.475-476

2018

Volltextzugriff (PDF)

Second line small molecule therapy options for treating chronic myeloid leukemia

Expert opinion on pharmacotherapy, 2017-01, Vol.18 (1), p.57-65

2017

Volltextzugriff (PDF)

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies

Expert opinion on biological therapy, 2024-04, Vol.24 (4), p.233-241

2024

Volltextzugriff (PDF)

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach

Frontiers in oncology, 2021-06, Vol.11

2021

Volltextzugriff (PDF)

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

Annals of hematology, 2019-08, Vol.98 (8), p.1919-1925

2019

Volltextzugriff (PDF)

Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows

Hematology reports, 2020-09, Vol.12 (11), p.8950-8950

2020

Volltextzugriff (PDF)

Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours

Expert review of hematology, 2022-11, Vol.15 (11), p.973-986

2022

Volltextzugriff (PDF)

TP53 mutations in therapy-related acute myeloid leukemia: still the dark side of the moon?

Polskie archiwum medycyny wewne̦trznej, 2023-01, Vol.133 (1)

2023

Volltextzugriff (PDF)

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells

Annals of hematology, 2014-11, Vol.93 (11), p.1819-1823

2014

Volltextzugriff (PDF)

Drug treatment options for acute promyelocytic leukemia

Expert opinion on pharmacotherapy, 2022-01, Vol.23 (1), p.117-127

2022

Volltextzugriff (PDF)

FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis

Leukemia research, 2015-04, Vol.39 (4), p.397-399

2015

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(129)

Publikationsform

Artikel
(148)
Berichte
(5)

Sprache

Englisch
(153)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(105)
Science & Technology
(105)
Hematology
(71)
Humans
(64)
Oncology
(52)
Female
(38)
Male
(38)
Middle Aged
(31)
Aged
(30)
Leukemia
(29)
Prognosis
(28)
Adult
(24)
Chronic Myeloid Leukemia
(24)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(20)
Aged, 80 And Over
(17)
Patients
(17)
Chemotherapy
(16)
Medicine
(16)
Medicine & Public Health
(16)
Treatment Outcome
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Ponatinib: A Review of Efficacy and Safety

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Maintenance therapy in AML: The past, the present and the future

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 -Mutated AML Patients

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option

Second line small molecule therapy options for treating chronic myeloid leukemia

Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows

Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours

TP53 mutations in therapy-related acute myeloid leukemia: still the dark side of the moon?

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells

Drug treatment options for acute promyelocytic leukemia

FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis

Suchergebnisse filtern